Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens

Dana Orange, Mayu Frank, Suyan Tian, Athanasios Dousmanis, Ronen Marmur, Noreen Buckley, Salina Parveen, Jerome J. Graber, Nathalie Blachère, Robert B. Darnell

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Tumor treatment is the mainstay of therapy for paraneoplastic neurologic disorders (PNDs), but it is only effective in some cases and other treatment options are limited. Objective: To evaluate the short-term use of a combination of prednisone and tacrolimus for acute neurologic worsening in PND in which intracellular antigens are targeted. Design: Retrospective single-center case series of patients with PND treated with tacrolimus. Setting: The Rockefeller University Hospital, a research hospital in New York, New York. Patients: Twenty-six patients with PND with high titer (≥1:1000) anti-HuD, anti-Yo, or anti-CRMP5 autoantibodies were enrolled. Patients were referred from Memorial Sloan Kettering Cancer Center or self-referred. Two patients discontinued intervention owing to adverse events. Interventions: Patients were treated with tacrolimus, 0.15-0.30 mg/kg per day, in 2 divided oral doses with 60 mg per day of oral prednisone, tapered off during 1 to 4 weeks. Main Outcome Measures: The primary outcome measure was median survival. Neurologic examinations before and after treatment as well as adverse events are described. Results: Median survival time was 52 months from time of diagnosis. Some patients experienced neurologic improvement that was functionally meaningful. The incidence of adverse events was similar to that generally reported with tacrolimus. Conclusions: A short course of prednisone and tacrolimus to target central nervous system T cells in patients with PND with acute neurologic decline in which intracellular antigens are targeted was well tolerated and warrants further study.

Original languageEnglish (US)
Pages (from-to)1132-1140
Number of pages9
JournalArchives of Neurology
Volume69
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Nervous System Paraneoplastic Syndromes
Tacrolimus
Antigens
Nervous System Diseases
Prednisone
Nervous System
Outcome Assessment (Health Care)
Survival
Suppression
Syndrome
Neurologic Examination
Therapeutics
Autoantibodies
Neoplasms
Central Nervous System
T-Lymphocytes

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Orange, D., Frank, M., Tian, S., Dousmanis, A., Marmur, R., Buckley, N., ... Darnell, R. B. (2012). Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Archives of Neurology, 69(9), 1132-1140. https://doi.org/10.1001/archneurol.2012.595

Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. / Orange, Dana; Frank, Mayu; Tian, Suyan; Dousmanis, Athanasios; Marmur, Ronen; Buckley, Noreen; Parveen, Salina; Graber, Jerome J.; Blachère, Nathalie; Darnell, Robert B.

In: Archives of Neurology, Vol. 69, No. 9, 09.2012, p. 1132-1140.

Research output: Contribution to journalArticle

Orange, D, Frank, M, Tian, S, Dousmanis, A, Marmur, R, Buckley, N, Parveen, S, Graber, JJ, Blachère, N & Darnell, RB 2012, 'Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens', Archives of Neurology, vol. 69, no. 9, pp. 1132-1140. https://doi.org/10.1001/archneurol.2012.595
Orange, Dana ; Frank, Mayu ; Tian, Suyan ; Dousmanis, Athanasios ; Marmur, Ronen ; Buckley, Noreen ; Parveen, Salina ; Graber, Jerome J. ; Blachère, Nathalie ; Darnell, Robert B. / Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. In: Archives of Neurology. 2012 ; Vol. 69, No. 9. pp. 1132-1140.
@article{4551c0ea5f21458e96b09738b7e98643,
title = "Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens",
abstract = "Background: Tumor treatment is the mainstay of therapy for paraneoplastic neurologic disorders (PNDs), but it is only effective in some cases and other treatment options are limited. Objective: To evaluate the short-term use of a combination of prednisone and tacrolimus for acute neurologic worsening in PND in which intracellular antigens are targeted. Design: Retrospective single-center case series of patients with PND treated with tacrolimus. Setting: The Rockefeller University Hospital, a research hospital in New York, New York. Patients: Twenty-six patients with PND with high titer (≥1:1000) anti-HuD, anti-Yo, or anti-CRMP5 autoantibodies were enrolled. Patients were referred from Memorial Sloan Kettering Cancer Center or self-referred. Two patients discontinued intervention owing to adverse events. Interventions: Patients were treated with tacrolimus, 0.15-0.30 mg/kg per day, in 2 divided oral doses with 60 mg per day of oral prednisone, tapered off during 1 to 4 weeks. Main Outcome Measures: The primary outcome measure was median survival. Neurologic examinations before and after treatment as well as adverse events are described. Results: Median survival time was 52 months from time of diagnosis. Some patients experienced neurologic improvement that was functionally meaningful. The incidence of adverse events was similar to that generally reported with tacrolimus. Conclusions: A short course of prednisone and tacrolimus to target central nervous system T cells in patients with PND with acute neurologic decline in which intracellular antigens are targeted was well tolerated and warrants further study.",
author = "Dana Orange and Mayu Frank and Suyan Tian and Athanasios Dousmanis and Ronen Marmur and Noreen Buckley and Salina Parveen and Graber, {Jerome J.} and Nathalie Blach{\`e}re and Darnell, {Robert B.}",
year = "2012",
month = "9",
doi = "10.1001/archneurol.2012.595",
language = "English (US)",
volume = "69",
pages = "1132--1140",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens

AU - Orange, Dana

AU - Frank, Mayu

AU - Tian, Suyan

AU - Dousmanis, Athanasios

AU - Marmur, Ronen

AU - Buckley, Noreen

AU - Parveen, Salina

AU - Graber, Jerome J.

AU - Blachère, Nathalie

AU - Darnell, Robert B.

PY - 2012/9

Y1 - 2012/9

N2 - Background: Tumor treatment is the mainstay of therapy for paraneoplastic neurologic disorders (PNDs), but it is only effective in some cases and other treatment options are limited. Objective: To evaluate the short-term use of a combination of prednisone and tacrolimus for acute neurologic worsening in PND in which intracellular antigens are targeted. Design: Retrospective single-center case series of patients with PND treated with tacrolimus. Setting: The Rockefeller University Hospital, a research hospital in New York, New York. Patients: Twenty-six patients with PND with high titer (≥1:1000) anti-HuD, anti-Yo, or anti-CRMP5 autoantibodies were enrolled. Patients were referred from Memorial Sloan Kettering Cancer Center or self-referred. Two patients discontinued intervention owing to adverse events. Interventions: Patients were treated with tacrolimus, 0.15-0.30 mg/kg per day, in 2 divided oral doses with 60 mg per day of oral prednisone, tapered off during 1 to 4 weeks. Main Outcome Measures: The primary outcome measure was median survival. Neurologic examinations before and after treatment as well as adverse events are described. Results: Median survival time was 52 months from time of diagnosis. Some patients experienced neurologic improvement that was functionally meaningful. The incidence of adverse events was similar to that generally reported with tacrolimus. Conclusions: A short course of prednisone and tacrolimus to target central nervous system T cells in patients with PND with acute neurologic decline in which intracellular antigens are targeted was well tolerated and warrants further study.

AB - Background: Tumor treatment is the mainstay of therapy for paraneoplastic neurologic disorders (PNDs), but it is only effective in some cases and other treatment options are limited. Objective: To evaluate the short-term use of a combination of prednisone and tacrolimus for acute neurologic worsening in PND in which intracellular antigens are targeted. Design: Retrospective single-center case series of patients with PND treated with tacrolimus. Setting: The Rockefeller University Hospital, a research hospital in New York, New York. Patients: Twenty-six patients with PND with high titer (≥1:1000) anti-HuD, anti-Yo, or anti-CRMP5 autoantibodies were enrolled. Patients were referred from Memorial Sloan Kettering Cancer Center or self-referred. Two patients discontinued intervention owing to adverse events. Interventions: Patients were treated with tacrolimus, 0.15-0.30 mg/kg per day, in 2 divided oral doses with 60 mg per day of oral prednisone, tapered off during 1 to 4 weeks. Main Outcome Measures: The primary outcome measure was median survival. Neurologic examinations before and after treatment as well as adverse events are described. Results: Median survival time was 52 months from time of diagnosis. Some patients experienced neurologic improvement that was functionally meaningful. The incidence of adverse events was similar to that generally reported with tacrolimus. Conclusions: A short course of prednisone and tacrolimus to target central nervous system T cells in patients with PND with acute neurologic decline in which intracellular antigens are targeted was well tolerated and warrants further study.

UR - http://www.scopus.com/inward/record.url?scp=84866141837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866141837&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2012.595

DO - 10.1001/archneurol.2012.595

M3 - Article

C2 - 22566506

AN - SCOPUS:84866141837

VL - 69

SP - 1132

EP - 1140

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -